Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease
Clinical Study on the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Mild and Moderate Alzheimer's Disease
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Status

    Unknown status
  • Study Participants

The primary purpose of this study is to evaluate the safety and the efficacy of (Human Umbilical Cord-Derived Mesenchymal Stem Cells) UCMSCs for patients with Alzheimer's disease (AD).
Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Randomized, Safety/ Efficacy Study Official Title: Multicenter, Randomized, Double-blind, Placebo Controlled Trial of UCMSCs in Subjects With Alzheimer's Disease
Study Started
Oct 20
Primary Completion
Oct 31
Study Completion
Oct 31
Last Update
Apr 26

Biological UCMSCs

Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)

  • Other names: Human Umbilical Cord Derived Mesenchymal

Biological Placebo

Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)

UCMSCs Experimental

Subjects with Alzheimer's Disease Intervention: UCMSCs

Placebo Placebo Comparator

Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)


Inclusion Criteria:

Ages 50 to 80, male and female.
A diagnosis of probable AD and Mixed Dementia according to the criteria of the NINCDS-ADRDA
Treatment with other cholinesterase inhibitors, such as a stable dose of donnepiazide tablets (5mg/ day or 10mg/ day) or the use of heavy tartaric acid karbalin capsules, is currently being used.
MMSE score between 10 and 26.
Voluntarily participating subject who sign the Inform Concent

Exclusion Criteria:

Caused by other reasons of dementia (vascular dementia, infectious disease of the central nervous system (such as HIV, syphilitic dementia), g - she's disease, Parkinson's disease, Lou gehrig's disease, huntington's disease DLB, traumatic brain dementia, other physical and chemical factors (such as: drug poisoning, alcoholism, carbon monoxide poisoning and other dementia), important body disease (such as hepatic encephalopathy, pulmonary encephalopathy dementia), intracranial placeholder lesions, endocrine system disease, such as thyroid disease, parathyroid disease), and vitamins and other causes of dementia)
The Hamilton depression scale (HAMD) score > 17, or patients with a history of depression or other psychiatric or psychiatric disorders.
The Hachinski ischemic index scale (HIS) scored > 4.
The brief intelligence status examination scale (MMSE) score of 10 patients.
Liver function (ALT, AST) exceeded the normal range limit of 1.5 times, SCr exceeded normal range upper limit, white blood cell count < 4.0 x 109/L or platelet < 100 x 109/L, hemoglobin < 100g/L.
Patients with type 1 diabetes, obstructive pulmonary disease (copd) or asthma, vitamin B12 or folate deficiency patients, not control good digestion, liver, kidney, endocrine and cardiovascular system diseases (especially sick sinus syndrome and conduction block), patients with HIV/AIDS, syphilis, active tuberculosis, etc.
A person with cancer or a history of cancer.
People with a clinically significant history of stroke, who have had a seizure or a head injury in the past two years, have caused the disorder.
There is a history of congestive heart failure or a history of myocardial infarction, and a blood disease in two years.
Drug clinical trials were performed within 3 months of screening.
Anti-ad agents are being used in addition to the programme requirements.
The use of stem cell therapy in half a year.
People with history of alcoholism and substance abuse, allergies, or history of allergies.
Patients who had been hospitalized for more than 3 months before screening. of allergies.
The researchers think it is inappropriate to participate in this clinical trial.
No Results Posted